GPR179: A Potential Drug Target for Pain, Inflammation and Neurodegenerative Disorders
GPR179: A Potential Drug Target for Pain, Inflammation and Neurodegenerative Disorders
GPR179 (also known as GPR158L) is a protein that is expressed in various tissues throughout the body, including the brain, pancreas, and gastrointestinal tract. It is a G protein-coupled receptor (GPCR), which means it is a transmembrane protein that is involved in the transfer of signals from intrinsically released molecules to the extracellular environment.
GPR179 has been identified as a potential drug target due to its involvement in a variety of physiological processes, including pain perception, inflammation, and neurodegeneration. Its function in these processes has led to its potential as a therapeutic agent for a range of diseases, including cancer, neurodegenerative disorders, and chronic pain.
One of the key reasons for GPR179's potential as a drug target is its involvement in pain perception. GPR179 is known to play a role in the transmission of pain signals from the gut to the brain, and has been shown to contribute to the development of chronic pain conditions. By targeting GPR179 with drugs, researchers may be able to reduce or alleviate pain in a variety of conditions.
Another potential application of GPR179 as a drug target is its role in inflammation. GPR179 has been shown to be involved in the regulation of inflammation, and has been linked to the development of various inflammatory diseases. By targeting GPR179 with drugs, researchers may be able to reduce inflammation and improve the treatment of inflammatory disorders.
In addition to its potential as a pain and inflammation drug target, GPR179 is also being studied for its potential as a neurodegenerative disorder drug target. GPR179 has been shown to be involved in the development and progression of neurodegenerative disorders, including Alzheimer's disease and Parkinson's disease. By targeting GPR179 with drugs, researchers may be able to slow or halt the progression of neurodegenerative disorders.
GPR179 is also being studied as a potential biomarker for a variety of diseases, including cancer and neurodegenerative disorders. By measuring the expression of GPR179 in various tissues and fluids, researchers may be able to use GPR179 as a diagnostic or predictive marker for these diseases.
Targeting GPR179 with drugs may also have potential side effects, as with any drug. However, researchers are currently in the process of studying the safety and efficacy of targeting GPR179, and are working to identify potential strategies for minimizing these side effects.
Overall, GPR179 is a protein that has the potential to be a drug target for a variety of diseases, including cancer, neurodegenerative disorders, and chronic pain. By targeting GPR179 with drugs, researchers may be able to improve the treatment of these diseases and improve the quality of life for patients.
Protein Name: G Protein-coupled Receptor 179
Functions: Orphan receptor, involved in vision. Required for signal transduction through retinal depolarizing bipolar cells
The "GPR179 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about GPR179 comprehensively, including but not limited to:
• general information;
• protein structure and compound binding;
• protein biological mechanisms;
• its importance;
• the target screening and validation;
• expression level;
• disease relevance;
• drug resistance;
• related combination drugs;
• pharmacochemistry experiments;
• related patent analysis;
• advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai
More Common Targets
GPR18 | GPR180 | GPR182 | GPR183 | GPR19 | GPR199P | GPR20 | GPR21 | GPR22 | GPR25 | GPR26 | GPR27 | GPR3 | GPR31 | GPR32 | GPR33 | GPR34 | GPR35 | GPR37 | GPR37L1 | GPR39 | GPR4 | GPR42 | GPR45 | GPR50 | GPR52 | GPR55 | GPR6 | GPR61 | GPR62 | GPR63 | GPR65 | GPR68 | GPR75 | GPR75-ASB3 | GPR78 | GPR79 | GPR82 | GPR83 | GPR84 | GPR84-AS1 | GPR85 | GPR87 | GPR88 | GPR89A | GPR89B | GPRACR | GPRASP1 | GPRASP2 | GPRASP3 | GPRC5A | GPRC5B | GPRC5C | GPRC5D | GPRC5D-AS1 | GPRC6A | GPRIN1 | GPRIN2 | GPRIN3 | GPS, PLAT and transmembrane domain-containing protein | GPS1 | GPS2 | GPS2P1 | GPSM1 | GPSM2 | GPSM3 | GPT | GPT2 | GPX1 | GPX1P1 | GPX2 | GPX3 | GPX4 | GPX5 | GPX6 | GPX7 | GPX8 | GRAMD1A | GRAMD1B | GRAMD1C | GRAMD2A | GRAMD2B | GRAMD4 | GRAMD4P2 | GRAMD4P5 | GRAMD4P7 | Granzyme | GRAP | GRAP2 | GRAPL | GRAPL-AS1 | GRASLND | GRB10 | GRB14 | GRB2 | GRB7 | GREB1 | GREB1L | GREM1 | GREM1-AS1
